This is a working overview of Albumin conjugation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Hospital Facilities == .Theodor Bilharz research Institute Hospital is a tertiary hospital in Waraq El-Hadar, Giza, Egypt. · Six surgical theatres .Three ICU units ( 11 beds general medical ICU, 4 beds Surgical post-operative and 12 beds Hepatic ICU) .240 beds of Hepatology, Nephrology, General Medicine, Urosurgery, General Surgery, Intensive Care Unit. .Diagnostic Radiology department. . Interventional Radiology Unit. · Endoscopic facilities (gastroduodenoscopy, colonoscopy and ERCP) with ultrasonography and Doppler-electrocardiography. · Laparoscopic facilities for diagnostic and therapeutic purposes. · Minimal invasive urosurgery utilizing ureterorenoscopy; nephroscope and cystoscope, under fluoroscopic and endo-camera guidance. · Blood gas monitoring with estimation of serum electrolytes. · Fluoroscopy guided angio-table. · Twenty machines for haemodialysis. . Blood bank and various laboratories
== Chemistry == The method for synthesis of nicomorphine, which involves treating anhydrous morphine base with nicotinic anhydride at 130 °C, was published by Pongratz and Zirm in Monatshefte für Chemie in 1957, simultaneously with the two analogues nicocodeine and nicodicodeine in an article about amides and esters of various organic acids.
Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure. The most common side effects include infections, hypertension, infusion-related reactions, and pyrexia. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. In June 2025, the U.S. Food and Drug Administration (FDA) approved emapalumab-lzsg for the treatment of macrophage activation syndrome (MAS) in patients with Still’s disease.
February 9 The second impeachment trial of Donald Trump begins. He is acquitted four days later, February 13 with a 57–43 vote in the Senate, ten votes short of the required two-thirds majority for conviction. COVID-19 drug development: The FDA issues an emergency use authorization (EUA) for bamlanivimab and etesevimab. February 11 President Biden terminates the national emergency declaration on the US-Mexico border which President Trump had used to pay for the wall. In Fort Worth, Texas, at least six people are killed in an accident involving 133 vehicles on Interstate 35W, affected by weather conditions left by a snowstorm system. February 12 The United States Senate votes by unanimous consent to award United States Capitol Police officer Eugene Goodman the Congressional Gold Medal for keeping rioters away from the Senate chamber during the storming of the United States Capitol. The U.S. Food and Drug Administration approves Cosela as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression. February 15 – House Speaker Nancy Pelosi announces that Congress will establish a 9/11-styled commission to investigate the January 6 riot at the United States Capitol. February 13–17 – A major winter storm kills 58 people in the United States (and 12 in Mexico) and causes over 9,724,000 power outages across 13 states in the Midwest and Southwest, with Southwest Power Pool declaring an "energy emergency". February 17 COVID-19 pandemic: North Dakota confirms their first case of the UK variant of SARS-CoV-2.
Sources: en.wikipedia.org
==== Cardiovascular ==== Other side-effects can include alterations in the structure of the heart, such as enlargement and thickening of the left ventricle, which impairs its contraction and relaxation, and therefore reducing ejected blood volume. Possible effects of these alterations in the heart are hypertension, cardiac arrhythmias, congestive heart failure, heart attacks, and sudden cardiac death. These changes are also seen in non-drug-using athletes, but steroid use may accelerate this process. However, both the connection between changes in the structure of the left ventricle and decreased cardiac function, as well as the connection to steroid use have been disputed. AAS use can cause harmful changes in cholesterol levels: Some steroids cause an increase in LDL cholesterol and a decrease in HDL cholesterol.
=== CANOPUS: Compound class prediction === CANOPUS is short for class assignment and ontology prediction using mass spectrometry. It predicts the compound classes from the molecular fingerprint predicted by CSI:FingerID. This approach is completely database-free, i.e. it is not even limited to molecules that are listed in structure databases. CANOPUS employs a deep neural network (DNN) to predict 2,497 compound classes. The DNN was trained on 4.10 million compound structures with compound classes assigned by ClassyFire. No MS/MS data was used for training, but instead simulated 'realistic' probabilistic fingerprints for the training molecular structures were used. The DNN predicts all compound classes simultaneously. For full biological datasets, CANOPUS provides a comprehensive overview of compound classes present in the sample and allows for comparisons between different cohorts at compound class level.
==== Germany ==== In Germany all of the major parties are loosely associated with research foundations that play some role in shaping policy, but generally from the more disinterested role of providing research to support policymakers than explicitly proposing policy. These include the Konrad-Adenauer-Stiftung (Christian Democratic Union-aligned), the Friedrich-Ebert-Stiftung (Social Democratic Party-aligned), the Hanns-Seidel-Stiftung (Christian Social Union-aligned), the Heinrich-Böll-Stiftung (aligned with the Greens), Friedrich Naumann Foundation (Free Democratic Party-aligned) and the Rosa Luxemburg Foundation (aligned with Die Linke). The German Institute for International and Security Affairs is a foreign policy think tank. Atlantic Community is an independent, non-partisan and non-profit organization set up as a joint project of Atlantische Initiative e.V. and Atlantic Initiative United States. The Institute for Media and Communication Policy deals with media-related issues. Transparency International is a think tank on the role of corporate and political corruption in international development.
aid, though it was under the first five years of the Plan Colombia. In March 2015, it was revealed DEA agents were participating in drug cartel-funded sex parties with prostitutes. Agents were provided with expensive gifts, weapons, and money from drug cartel members. As a result, the head of the US Drug Enforcement Administration, Michele Leonhart, announced her retirement. According to the 2022 Truth Commission report, the 2019 arrest of Jesús Santrich on drug trafficking charges, which was a joint operation by the DEA and Colombian Attorney General Néstor Humberto Martínez, was intended to send a message from the Colombian Attorney General's to the Colombian public that the peace process had failed. Santrich's arrest led to hundreds of ex-guerrillas taking up arms again, which jeopardized the peace process.
a known amount of anti-HbA1c antibody is added to the sample because only one binding site is available per HbA1c molecule (the glycated N-terminal valine on a beta chain), the antibody-HbA1c complex is small and soluble excess polyhapten is added to the sample. The polyhapten is several HbA1c-like epitopes bound together excess antibody cross-links with the polyhapten and forms large complexes which are insoluble and make the solution turbid Turbidity is inversely proportional to HbA1c concentration Concentration of HbA1c divided by concentration of total Hb (e.g. measured by absorptiometry) gives a percentage HbA1c
Sources: en.wikipedia.org
=== Ion mobility separation === There are different types of ion mobility spectrometers and there are different types of mass spectrometers. In principle it is possible to combine every type of the former with any type of the latter. However, in the real world, different types of ion mobility are coupled with different types of mass spectrometers to achieve reasonable sensitivity. The main types of ion mobility spectrometers that have been coupled to a mass spectrometer for IM-MS applications are discussed below.
== Contraindications == Sulfanilamide is contraindicated in those known to be hypersensitive to sulfonamides, in nursing mothers, during pregnancy near term, and in infants less than two months of age.
=== Radiation therapy === Radiation therapy is the most frequently used treatment for hypersomatotropic cats. Radiation therapy is expensive, limited in availability, cost, frequent anaesthetic, and the unpredictable outcomes for hormonal control. The resolution or improvement of neurological signs is the most consistent effect. Improvement diabetes symptoms is less consistent. One study found an average of 5 weeks for improvement to glycaemic control with all cats seeing an improvement within 20 weeks. The same study found 6 of the 14 cats to achieve diabetic remission within 6 months with an average of 3.6 months. Diabetic remission may occur as late as a year after radiotherapy. Improvement of diabetic symptoms occurs in roughly 70-80% of cases, diabetic remission occurs in roughly 50%. The physical acromegalic changes often persistent or have only slight improvement. High IGF-1 levels have been reported in cats following radiation therapy. Of note is that in several of those cases the patient had good control of diabetic symptoms or was in remission. Radiation therapy is tolerated by the majority of cats. Side effects such as ischaemic brain necrosis and hearing loss are rare and proper fractionation protocol can prevent these effects from occurring; hypopituitarism has not been reported in cats, despite being a common adverse effect in humans. Survival times for cats after radiation therapy has been reported to be up to 5 years.
==== Electrolyte imbalances ==== Electrolytes like Na, K, Ca, and P can all cause mimicking symptoms when high or low. Most commonly, hypokalemia, or low K, is the culprit, since many common drugs decrease this electrolyte.
=== Early pre-commercial research === In 1761, Ebenezer Kinnersley demonstrated heating a wire to incandescence. However such wires tended to melt or oxidize very rapidly (burn) in the presence of air. Limelight became a popular form of stage lighting in the early 19th century, by heating a piece of calcium oxide to incandescence with an oxyhydrogen torch. In 1802, Humphry Davy used what he described as "a battery of immense size", consisting of 2,000 cells housed in the basement of the Royal Institution of Great Britain, to create an incandescent light by passing the current through a thin strip of platinum, chosen because the metal had an extremely high melting point. It was not bright enough nor did it last long enough to be practical, but it was the precedent behind the efforts of scores of experimenters over the next 75 years. Davy also demonstrated the electric arc, by passing high current between two pieces of charcoal. For the next 40 years, much research was given to turning the carbon arc lamp into a practical means of lighting. The carbon arc itself was dim and violet in color, emitting most of its energy in the ultraviolet, but the positive electrode was heated to just below the melting point of carbon and glowed very brightly with incandescence very close to that of sunlight. Arc lamps burned up their carbon rods very rapidly, expelled dangerous carbon monoxide, and tended to produce outputs in the tens of kilowatts. Therefore, they were only practical for lighting large areas, so researchers continued to search for a way to make lamps suitable for home use.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.